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EDITORIAL

Erythropoiesis-Stimulating Agents and
Cancer: Myth or Truth

E

rythropoiesis-stimulating agents (ESAs) have been
implicated in causing cancer progression. This belief
has been largely based on trials in the early 2000s of ESA
use in malignancy with high hemoglobin (Hgb) targets
and large ESA doses to attain the targets. More recent trials
using ESA doses with Hgb targets similar to current goal
levels in CKD have not conﬁrmed this increased risk of
cancer progression for most malignancies.
Anemia in patients with malignancy was associated
with increased mortality and decreased response to
therapy. Correction of anemia was postulated to
enhance survival rates1,2 by increasing tumor
oxygenation,
which
would
lead
to
greater
susceptibility to chemotherapy and radiotherapy.3-7
However, the outcomes of three early trials using
ESAs were abysmal. The double-blinded, placebocontrolled trial of erythropoietin (EPO) to treat head
and neck cancer patients with anemia undergoing
radiotherapy (n ¼ 351) examined response to radiotherapy when anemic patients (Hgb: ,12 g/dL for
women and ,13 g/dL for men) were corrected to higher
target levels (.14 g/dL in women and .15 g/dL in
men).3 The ESA group had increased cancer progression
(relative risk [RR], 1.69; P ¼ 0.007) and death (RR, 1.39;
P ¼ 0.02). The Danish Head and Neck Cancer (DAHANCA) 10 trial randomized 522 patients with or
without darbepoetin alfa (DA) to a target Hgb of 14.0–
15.5 g/dL.4 The placebo group had a 10% improved survival rate (P ¼ 0.01) compared with the ESA-treated
group, prompting trial termination. The multicenter,
randomized, double-blinded, placebo-controlled Breast
Cancer Erythropoietin Trial (BEST) of women with metastatic breast cancer receiving ﬁrst-line chemotherapy
examined survival difference in those with EPO treatment for anemia vs placebo.8 Hgb was targeted to 12–
14 g/dL in subjects with baseline levels of 13 g/dL.
The study was also terminated early as the primary
endpoint of 12-month survival in the ESA-treated group
was worse than the placebo group (70% vs 76%). This
was attributed to cancer progression and increased
thrombotic and vascular events in the ESA group.

A Cochrane Database meta-analysis of 91 trials also
documented greater mortality risk in ESA-treated participants with malignancy, deﬁned as death occurring up to
30 days after active study protocol (hazard ratio [HR],
1.170; 95% conﬁdence interval [CI], 1.06 to 1.29), with
reduced overall survival (HR, 1.05; 95% CI, 1.00 to
1.11).9 These results were restricted to those with baseline
Hgb levels .12 g/dL—a level that currently prohibits the
initiation of ESA therapy. In trials restricted to active
chemotherapy, only modest trends toward on-study
(odds ratio [OR], 1.10; 95% CI, 0.98 to 1.24) and overall
mortality (OR, 1.04; 95% CI, 0.98 to 1.11) were recorded.
ESA use was associated with thromboembolic complications (RR, 1.52; 95% CI, 1.34 to 1.74) at any baseline Hgb.
In these trials, ESA doses were substantial (EPO b dose
of 300 IU/kg subcutaneously 3 times weekly,3 DA 150
mcg subcutaneously weekly,4 and EPO 40,000 U subcutaneously once weekly8) with high Hgb targets. Consistent
with the aforementioned trials, the Cochrane database
meta-analysis reported on trials with target Hgb levels
considerably higher than present targets with an upper
Hgb level ,14 g/dL in 54% of studies, ,15 g/dL in 24%,
and ,16 g/dL in 5%. The reasons for higher mortality
with ESA use in these early studies may have been attributable to enhanced thrombotic rates, given the considerable ESA doses required to achieve high Hgb targets.
This observation represents an adjunctive and/or alternative explanation to the possibility of cancer progression.5
In contrast to the ﬁndings of earlier trials, ESAs have not
been shown to increase tumor progression in the majority
of more recent human studies.9 Prior versions of the Cochrane meta-analysis included dosages of at least 300 U/
kg body weight per week (epoetin alfa and beta) delivered
for at least 4 weeks. This criterion was removed to include
studies or study arms with lower dosages. A metaanalysis of ESA use and safety outcomes, which included
Ó 2019 by the National Kidney Foundation, Inc. All rights reserved.
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25 studies with some measure of disease progression,10
found no signiﬁcant impact on cancer progression (OR,
1.01; 95% CI, 0.9 to 1.14). A summary of meta-analyses
of 56 trials and 16,336 participants also did not demonstrate any ESA effect(s) on disease advancement.11
A recent trial of 2098 women with metastatic breast cancer could not rule out a 15% increased risk of progressive
disease or death with EPO alfa use vs best standard of care
when Hgb was ,11 g/dL with target Hgb concentration
,12 g/dL.12 Although the median progression-free survival (HR, 1.089; 95% CI, 0.99 to 1.20) and median overall
survival (HR, 1.057; 95% CI, 0.95 to 1.18) exceeded the predeﬁned noninferiority margin of 1.15, which was the upper boundary of the 95% CI, the independent review
committee concluded that progression-free survival did
meet noninferiority criteria.
Based on data reporting increased mortality and thrombotic risk, the American Society of Clinical Oncology/
American Society of Hematology and the European
Society for Medical Oncology in 2010 developed guidelines for ESA use in patients with cancer. Advice was to
start ESA therapy in case of chemotherapy-induced
anemia for Hgb , 10 g/dL and to discontinue ESA therapy within one month of chemotherapy completion.13,14
The guidelines removed an optimal target Hgb level and
recommended
prescribing
the
lowest
possible
therapeutic ESA dose. For myeloma, non-Hodgkin’s
lymphoma, and chronic lymphocytic leukemia
patients, the American Society of Clinical Oncology/
American Society of Hematology authored two speciﬁc
recommendations. First, observe Hgb responses to
chemotherapy. Second, manage symptoms using red cell
transfusions, with the known risk of thromboembolic
disease documented in myeloma patients treated
with thalidomide, lenalidomide, doxorubicin, or
corticosteroids.13,15
Inferior outcomes associated with ESA use in malignancy were postulated as attributable activation of erythropoietin receptors (EpoRs) on tumor cells. Receptorligand engagement presumably would enhance the proliferation of tumor cells.16,17 Early studies revealed
expression of EpoR mRNA and protein by
immunoblotting on tumor cells. However, these ﬁndings
have been questioned due to the absence of negative
controls and lack of assessment of functional responses
to Epo. These ﬁndings may be due to the use of
nonspeciﬁc EpoR antibodies that identify multiple non–
EpoR proteins. In addition, these antibodies detect cytoplasmic EpoRs instead of functional membraneassociated EpoRs.18-20 Other studies have not shown
signiﬁcant gene ampliﬁcation of tumoral EpoR20 when using EpoR-speciﬁc monoclonal antibodies. These antibodies detected EpoR levels that were either
undetectable or 100-fold lower in tumor cell lines than
EpoR levels in positive-control hematopoietic cell lines.21
Disagreement regarding the presence or absence of
EpoR on tumor cells stems from the antibody used for
detection. Academic scientists have usually used polyclonal anti-EpoR antisera, whereas scientists working for
industry have used monoclonal antibodies.21 The absence

or rare functional responses to in vivo ESA administration
in tumor cell lines implies that tumor cell EpoR activation
does not represent a major mechanism for cancer spread.
Other mechanisms for ESA use leading to tumor progression include binding of EpoRs on activated monocytes and macrophages, repression of proinﬂammatory
genes with subsequent immunosuppression and tumor
enhancement, and triggering of pathways that increase
tissue delivery of oxygen to tumor. The latter potentially
leads to lymphangiogenesis with lymph node metastasis
with resultant tumoral progression.11,21-24
Oncology guidelines do not address speciﬁc treatment
of cancer patients with anemia in CKD. In 2009, the Trial
to Reduce Cardiovascular Events with Aranesp Therapy
(TREAT) compared DA treatment vs placebo randomizing diabetic CKD patients with estimated glomerular
ﬁltration rate levels from 20 to 60 mL/min per 1.73 m2
and anemia with Hgb #11 g/dL to a target of 13 g/dL.25
The DA therapy group did not have reduced risk of the
composite outcomes (death, cardiovascular event and
death, or ESRD) but had an increased incidence of fatal
and nonfatal strokes (HR, 1.92; 95% CI, 1.38 to 2.68;
P , 0.001). Uneasiness regarding greater mortality among
patients with cancer during the study led to changes in
protocol to exclude individuals with active cancer and discontinue DA in any patients who developed cancer. No
difference occurred in the number of cancer-related events
or deaths in the ESA-treated group; however, more
cancer-related deaths occurred in the ESA subgroup
with a history of cancer that preceded randomization by
at least 5 years (ESA, 14 deaths vs placebo, 1 death;
P ¼ 0.002). These ﬁndings implied that a previous history
of malignancy in combination with ESA use (which in this
trial targeted an Hgb level of 13 g/dL) may be harmful in
this diabetic CKD population.
The 2012 Kidney Disease: Improving Global Outcomes
(KDIGO) Clinical Practice Guidelines for anemia in CKD
recommended caution with initiation or maintenance of
ESA therapy in those with previous malignancy only after
assessment of the potential beneﬁts of reduction of anemia
symptoms and transfusion requirements vs the risk of
stroke, vascular access clotting, and hypertension for all
patients with CKD.26 ESAs were speciﬁcally recommended
for use with great caution, if at all, in CKD patients with
active malignancy, particularly when cure was anticipated
(grade 1B) and with a previous malignancy (grade 1C).
Information apropos the association of ESAs and incidence of novel cancers is limited. In the Surveillance of
Epoetin-Adverse Events of Stroke and Cancer (SEASCAN) cross-sectional study, 7415 individuals with CKD
of stages 4 or 5 received either 0, ,6 months, or
$6 months of EPO treatment.27 No signiﬁcant differences
in incident cancer diagnosis among EPO groups were established (2.4%, 3.4%, and 2.5% for 0, ,6-month, and $6month groups; P ¼ 0.836). Mean baseline Hgb levels were
10.3 and 10.0 in the ,6-month and $6-month groups,
respectively. The length of follow-up appeared relatively
short, thereby limiting conclusions.
A nested case-control study of 4574 patients on dialysis
evaluated ESA dose exposure 6–9 months before cancer
Adv Chronic Kidney Dis. 2019;26(4):221-224
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diagnosis.28 Exposure categories were unexposed, lowdose DA (,30 mcg/week), moderate-dose DA (30–70
mcg/week), and high-dose DA (.70 mcg/week) with
baseline Hgb levels of 10.6 g/dL in untreated and ESAtreated groups. Epoetin alfa doses were converted to DA
doses using a ratio of 200 EPO units to 1 mcg of DA.
With a median follow-up of 1.8 years (interquartile range,
0.9–3.1), DA exposure was associated with a higher risk of
cancer (OR, 1.04; 95% CI, 1.02 to 1.07). This increased risk
was observed in the high-dose group (OR, 1.77; 95% CI,
1.18 to 2.66), which was not encountered among the other
dose groups compared to the unexposed group. Subjects
with high-dose ESA exposure may have incurred an inﬂammatory process or experienced a “missed” prior malignancy to explain the increased cancer risk in addition
to or instead of the ESA-induced or ESA-accelerated cancer growth.
In summary, data are insufﬁcient to support an association of low-dose ESA administration with increased cancer
risk. Although one trial could not rule out increased risk of
progression with a Hgb target ,12 g/dL, most studies
show that cancer patients with CKD had an increased mortality risk with ESA only when baseline Hgb concentrations exceeded 12 g/dL and targets were 13–16 g/dL.10,27
The paucity of data supporting tumor progression in
most malignancies may result from an ESA effect limited
to speciﬁc tumor types such as head, neck, and breast
cancers. Alternatively, the contribution of elevated target
Hgb level, high ESA dose, lack of anemia before starting
therapy, or a combination of these factors to the poor
outcomes associated with early studies of ESA therapy is
unclear. There are worse outcomes independent of cancer
progression with high Hgb targets, such as stroke and
thromboembolic risk, with the latter risk being increased
further with malignancy.
CKD patients with active malignancy may have anemia
due to chemotherapy, radiation treatment, inﬂammation,
and multiple venipunctures, in addition to the anemia of
Epo deﬁciency, iron deﬁciency, and inﬂammation from
CKD. KDIGO anemia guidelines cautiously recommend
ESA initiation with previous or active malignancy, whereas
the United States Food and Drug Administration recommends the following: ESA use only during chemotherapy
when anemia is ascribed to chemotherapy and no ESA
administration if chemotherapy is considered curative.
However, cancer patients with CKD or ESRD will have
continued ESA requirements beyond the period of chemotherapy and cure of cancer. Transfusions in patients with
CKD/ESRD may be problematic due to vascular access, volume overload with transfusions on nondialysis days, or an
inability to provide transfusions during dialysis. ESA
symptom management from the anemia in CKD and transfusion reduction may be more beneﬁcial to an individual
than the small potential for incident cancer risk.
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